Professor of Oncological Imaging

Professor of Oncological Imaging – University of Cambridge School of Clinical Medicine.

Honorary Consultant Radiologist  – Addenbrooke’s Hospital, Cambridge. University Hospitals NHS Foundation Trust.

Specialty: Cancer Imaging, Genitourinary Imaging, MRI, PET/CT, PET/MR

E-mail: : Evis Sala Tel.: +44(0)1223746440

Radiogenomics and Quantitative Imaging Group

Professor Evis Sala is pleased to consider applications from prospective PhD students.

Profile

Evis Sala, MD, PhD, FRCR, is the Imaging lead for the CRUK Cambridge Centre Integrative Cancer Medicine Theme.

Dr Sala is an academic radiologist with a special interest in Cancer Imaging. She is the Professor of Oncological Imaging at the University of Cambridge, UK. Previously, she served as Chief of Body Imaging Service at Memorial Sloan Kettering Cancer Center and Professor of Radiology, Weill Cornell Medical College in New York until December 2017. Before joining the Memorial Sloan Kettering in July 2012, she was a University Lecturer in Radiology and Specialty Teaching Director (Radiology) at the University of Cambridge, UK. She obtained her PhD from University of Cambridge, UK in 2000 and completed her training in Clinical Radiology at Cambridge, UK in August 2005.

She leads the Radiogenomics and Quantitative Imaging Group in the Department of Radiology.  Her current research focuses on integrated diagnostics, through the clinical development and validation of functional imaging biomarkers to rapidly evaluate treatment response using physiologic and metabolic tumour habitat imaging. Her research in the new field of “radio genomics” has focused on understanding the molecular basis of cancer by demonstrating the phenotypic patterns which occur as a result of multiple genetic alterations that interact with the tumour microenvironment to drive the disease in several tumours types. Her work integrates quantitative imaging methods for evaluation of spatial and temporal tumour heterogeneity with genomics, proteomics and metabolomics. She is also working on development and clinical translation of several novel PET tracers.

Dr. Sala is active in many academic organizations. She is the Chair of Radiology Society of North America (RSNA) Oncologic Imaging Track, serves on the Oncologic Imaging and Therapies Task Force of RSNA and the Genitourinary Imaging Subcommittee of European Society of Radiology. She is a member of Board of Trustees of the International Society for Magnetic Resonance in Medicine (ISMRM), the International Cancer Imaging Society (ICIS) and The European Society of Urogenital Radiology (ESUR). Dr Sala is an Editorial Board member and Head of Oncology Section of European Radiology. In recognition for her contribution to education and research in oncological imaging, she was elected as a Fellow of ICIS in 2014, a Fellow of ISMRM in 2015, a fellow of ESUR in 2018 and received the RSNA Honoured Educator Award in 2014 and 2017.

Professional Education

Current Research

Cancer Imaging, Molecular Imaging, Radiogenomics.

Radiogenomics and Quantitative Imaging Group

Last 5 Publications

Top 5 Publications

• Sala E, Kataoka MY, Priest AN, Gill AB, McClean MA, Joubert I, Graves MJ, Crawford R, Jimenez-Linan M, Earl H, Hodgkin C, Griffiths JR, Lomas DJ, Brenton JD. Advanced Ovarian Cancer: Multiparametric MR Imaging Demonstrates Response- and Metastasis-specific Effects. Radiology 2012 Apr; 263(1):149-159.
• Vargas HA, Micco M, Hong S, Goldman DA, Dao, F, Weigelt B, Soslow RA, Hricak H, Levine DA, Sala E. Association between morphologic computed tomography imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: A Hypothesis Generating Study. Radiology. 2015 Mar; 274(3):742-51
• Lakhman Y, Veeraraghavan H, Chaim J, Feier D, Goldman DA, Moskowitz CS, Nougaret S, Sosa RE, Vargas HA, Soslow R, Hricak H, Abu-Rustum NR, Sala E. Differentiation of Uterine leiomyosarcoma from atypical leiomyoma: diagnostic accuracy of qualitative MR imaging features and role of texture analysis. Eur Radiol 2016 PMID: 27921159 DOI:10.1007/s00330-016-4623-9.
• Parkinson CA, Gale D, Piskorz AM, Biggs H, Hodgkin C, Addley H, Freeman S, Moyle P, Sala E, Sayal K, Hosking K, Gounaris I, Jimenez-Linan M, Earl HE, Qian W, Rosenfeld N, Brenton JD. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective analysis. PLoS Med 2016 Dec 20;13(12):e1002198. doi:10.1371/journal.pmed.1002198.
• Jiménez-Sánchez A, Memmon D, Pourpe S, Veeraraghavan H, Li Y, Vargas HA, Gill MB, Park KJ, Zivanovic O, Konner J, Ricca J, Zamarin D, Walther T, Aghajanian C, Wolchok J, Sala E, Merghoub T, Snyder A, Miller ML. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell 2017;170(5):927-938.e92

Radiogenomics and Quantitative Imaging Group Members

• Helen Addley
• Luigi Alloj
• Tristan Barrett
• Lucian Beer
• Arnold Benjamin
• Mireia Crispin-Ortuzar
• Maria Delgado Ortet
• Lorena Escudero
• Amy Frary
• Susan Freeman
• Gabriel Funingana
• Martin Graves
• Andrew Gill
• Paula Martin-Gonzales
• Cathal McCague
• Mary McLean
• Iosif Mendichovszky
• Andrew Priest
• Marika Reinius
• Leonardo Rundo
• Hilal Sahin
• Eva Serrao
• Vencel Somai
• Nikita Shushentsev
• Stephan Ursprung
• Ramona Woitek